Literature DB >> 31848605

Breast Cancer Mortality After Implementation of Organized Population-Based Breast Cancer Screening in Norway.

Sofie Sebuødegård1, Edoardo Botteri2,3, Solveig Hofvind4.   

Abstract

BACKGROUND: We estimated breast cancer (BC) mortality reduction associated with invitations to a nationwide population-based screening program and with changes in treatment.
MATERIALS AND METHODS: BreastScreen Norway started in 1996 and became nationwide in 2005. It invites women aged 50-69 years to biennial mammographic screening. We retrieved individual-level data for 1 340 333 women from national registries. During 1996-2014 (screening window), women contributed person-years in noninvited and invited periods. We created comparable periods for 1977-1995 (prescreening window) by dividing the follow-up time for each woman into pseudo-noninvited and pseudo-invited periods. We estimated BC mortality for the four periods, using the so-called evaluation model: counting BC deaths in each period for all women diagnosed within the period and counting BC deaths and person-years after screening-age for those diagnosed within screening age. We used a multivariable flexible parametric survival model to estimate hazard ratio (HR) for the effect of invitation and improved treatment.
RESULTS: Using the regression approach, we found 5818 BC deaths across 16 533 281 person-years. Invitations to screening reduced BC mortality by 20% (HR = 0.80, 95% confidence interval [CI] = 0.70 to 0.91) among women 50 years and older and by 25% (HR = 0.75, 95% CI = 0.65 to 0.86) among screening-aged women. The treatment effect was 23% (HR = 0.77, 95% CI = 0.65 to 0.92) for women 50 years and older and 17% (HR = 0.83, 95% CI = 0.74 to 0.94) for screening-aged women.
CONCLUSION: We observed a similar reduction in BC mortality associated with invitations to screening and improvements in treatment during 1977-2014, among women 50 years and older.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Year:  2020        PMID: 31848605     DOI: 10.1093/jnci/djz220

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  7 in total

1.  Response to Zahl.

Authors:  Solveig Hofvind; Sofie Sebuødegård; Edoardo Botteri
Journal:  J Natl Cancer Inst       Date:  2020-11-01       Impact factor: 13.506

2.  RE: Breast Cancer Mortality After Implementation of Organized Population-Based Screening in Norway.

Authors:  Per-Henrik Zahl
Journal:  J Natl Cancer Inst       Date:  2020-11-01       Impact factor: 13.506

Review 3.  Comparing cancer and cardiovascular disease trends in 20 middle- or high-income countries 2000-19: A pointer to national trajectories towards achieving Sustainable Development goal target 3.4.

Authors:  Freddie Bray; Mathieu Laversanne; Bochen Cao; Cherian Varghese; Bente Mikkelsen; Elisabete Weiderpass; Isabelle Soerjomataram
Journal:  Cancer Treat Rev       Date:  2021-09-09       Impact factor: 12.111

4.  β-blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis.

Authors:  L Lukas Løfling; Nathalie C Støer; Erica K Sloan; Aeson Chang; Sara Gandini; Giske Ursin; Edoardo Botteri
Journal:  Br J Cancer       Date:  2022-06-20       Impact factor: 9.075

5.  Interpreting Breast Cancer Mortality Trends Related to Introduction of Mammography Screening: A Simulation Study.

Authors:  Torunn Heggland; Lars Johan Vatten; Signe Opdahl; Harald Weedon-Fekjær
Journal:  MDM Policy Pract       Date:  2022-10-08

6.  An analysis of time trends in breast and prostate cancer mortality rates in Lithuania, 1986-2020.

Authors:  Rūta Everatt; Daiva Gudavičienė
Journal:  BMC Public Health       Date:  2022-09-23       Impact factor: 4.135

Review 7.  The Role of the 21-Gene Recurrence Score® Assay in Hormone Receptor-Positive, Node-Positive Breast Cancer: The Canadian Experience.

Authors:  Mariya Yordanova; Saima Hassan
Journal:  Curr Oncol       Date:  2022-03-16       Impact factor: 3.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.